Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed genetic diagnosis of Prader-Willi Syndrome~* Age 12-65~* Obesity~* Age 12-17: BMI ≥ 95th percentile for age and gender~* Age 18-65: BMI ≥27 to ≤60 kg/m2~Exclusion Criteria:~* Subjects living in a group home ≥ 50% of the time~* Recent use (within 3 months) of weight loss agents including herbal medication~* Poorly controlled severe psychiatric disorders

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Intervention: ZGN-440 Placebo for Injectable Suspension
- ZGN-440 Injectable Suspension (1.8 mg) (Type: EXPERIMENTAL): Intervention: ZGN-440 for Injectable Suspension
- ZGN-440 Injectable Suspension (2.4 mg) (Type: EXPERIMENTAL): Intervention: ZGN-440 for Injectable Suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).